Market Place
Sourcing Support
Amryt Announces Positive Top Line Results from Ph3 Pediatric Trial of Lomitapide
05 Jan 2023 //
GLOBENEWSWIRE
Coming out of Chapter 11, Aegerion jumps into welcome arms of Irish pharma
25 Sep 2019 //
ENDPTS
Regeneron preps for 2020 filing for new cholesterol drug after trial success
18 Aug 2019 //
PHARMAPHORUM
Armed stellar if niche PhIII, Regeneron steers `breakthrough` cholesterol drug
14 Aug 2019 //
ENDPTS
Amryt to expand rare disease portfolio with $311m Aegerion merger
23 May 2019 //
PHARMAPHORUM
NHS England okays funding for cholesterol-lowering drug
09 Jul 2018 //
PHARMAPHORUM
Sticker Shock: The Real Cost Of America`s 10 Most Expensive Drugs
26 Jun 2018 //
FORBES
U.S. judge sentences Novelion`s Aegerion in drug marketing case
01 Feb 2018 //
REUTERS
Aegerion pleads guilty to US marketing violations
26 Sep 2017 //
PHARMA TIMES
Aegerion introduces Juxtapid in Japan for familial hypercholesterolemia
20 Dec 2016 //
PHARMABIZ
Novelion Therapeutics’ Subsidiary Launches Juxtapid in Japan
16 Dec 2016 //
GLOBENEWSWIRE
Aegerion Pharma inks licensing pact with Amryt Pharma for Lojuxta
06 Dec 2016 //
PHARMABIZ
Aegerion & QLT Complete Merger Transaction; QLT to Change Name to Novelion
29 Nov 2016 //
GLOBENEWSWIRE
Aegerion names Mary Szela CEO to replace controversial,overly talkative, Beer
08 Jan 2016 //
FIERCE PHARMA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.